Drug intelligence / Profile preview

Easyeye Dry

Development stage
Unknown
Lead developer
CNS Pharm Korea
Administration
Oral
01

Overview

Easyeye Dry is a high-dose omega-3 dietary supplement specifically formulated with a high ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA). Developed by Korea CNS Pharm, it is intended for the management of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). The supplement contains 1640 mg of DHA and 600 mg of EPA per daily dose (two capsules). It functions by modulating inflammatory and immune responses, specifically by inhibiting the synthesis of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha). Additionally, the high DHA content is thought to lower the melting point of meibomian lipids, thereby increasing the fluidity and secretion of meibum and stabilizing the tear film. Clinical trial data indicates that an 8-week regimen significantly improves tear break-up time (TBUT) and MGD scores in patients with mild to moderate dry eye.

Brand names
Easyeye Dry
Other names
high dose DHA omega-3 dietary supplement
02

Targets

TBXA2R (Thromboxane A2 receptor)TNFA (Tumor necrosis factor alpha (soluble))CysLTR (Cysteinyl leukotriene receptor family)IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on Easyeye Dry.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Easyeye Dry.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call